Prelude Therapeutics' PRT13722 Shows Promising Preclinical Results in HR+/HER2- Breast Cancer
Event summary
- Prelude Therapeutics presented preclinical data for PRT13722, a first-in-class, orally bioavailable KAT6A degrader, at the AACR Annual Meeting 2026.
- PRT13722 demonstrated complete tumor regressions as a monotherapy in HR+/HER2- breast cancer models.
- The company plans to file an Investigational New Drug (IND) application for PRT13722 in mid-2026 and initiate a Phase 1 clinical trial in the second half of 2026.
- PRT13722 showed an improved hematological safety profile compared to existing treatments.
The big picture
Prelude Therapeutics' PRT13722 represents a significant advancement in the treatment of HR+/HER2- breast cancer, leveraging targeted protein degradation to improve efficacy and safety. The company's focus on highly selective KAT6A degraders aligns with broader industry trends towards precision oncology and combination therapies. The successful translation of preclinical data into clinical outcomes could position PRT13722 as a key player in the breast cancer treatment landscape.
What we're watching
- Clinical Translation
- Whether PRT13722's preclinical efficacy and safety translate into clinical success.
- Regulatory Timeline
- The pace at which Prelude Therapeutics can secure IND approval and initiate Phase 1 trials.
- Combination Therapies
- How PRT13722's potential for combination with existing standards of care will impact its market positioning.
Related topics